AVANT TECHNOLOGIES INC (AVAI)
AVAI moved a median of 0.00% 30 minutes after news, and +1.17% by the close. How AVAI actually reacts to news — the realized, point-in-time move the market made, measured across 134 labeled events over the last three years with zero look-ahead.
AVAI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 33% | 125 |
| 30-min | 0.00% | 44% | 129 |
| 60-min | 0.00% | 47% | 131 |
| to close | +1.17% | 56% | 129 |
| Middle 50% of AVAI reactions | -0.53% to +2.70% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 134 |
Half of all AVANT TECHNOLOGIES INC news events land between -0.53% and +2.70% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when AVAI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AVAI's baseline. Nothing else.
Recent AVAI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Avaí Bio and Austrianova Hold First Joint Steering Committee Meeting with Ospedale San Raffaele for Diabetes Cell Therapy Program | Press release | GlobeNewswire | +0.00% | +1.27% | |
| Avaí Bio and Austrianova Successfully Encapsulate GMP-Quality Klotho-Producing Cells, Achieve Robust Klotho Secretion | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Avaí Bio and Austrianova Present Encapsulated Cell Approach to Sustained a-Klotho Delivery at 2026 Klotho Conference | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Avaí Bio and Austrianova Complete Adventitious Agent Testing of Master Cell Bank, Establish Working Cell Bank for a-Klotho Anti-Aging Therapy | Press release | GlobeNewswire | -7.33% | +0.00% | |
| Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick | Press release | GlobeNewswire | +0.00% | -11.86% | |
| Form 10-Q AVAI BIO, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.87% | |
| Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes | Press release | GlobeNewswire | -8.16% | -2.12% | |
| Avaí Bio and Austrianova Reach Agreement for Insulin-Producing Cells with Internationally Acclaimed Partner to Advance Diabetes Therapy | Press release | Canada Newswire | -10.12% | +3.26% | |
| Form 10-K AVAI BIO, INC. For: Mar 31 | SEC filing · Form 10-K | SEC EDGAR | +9.28% | +9.28% | |
| Form NT 10-K AVAI BIO, INC. For: Mar 31 | SEC filing · Form NT | SEC EDGAR | +0.00% | -18.93% | |
| Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy | Press release | Canada Newswire | +3.66% | -26.83% | |
| Form 8-K AVAI BIO, INC. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +1.66% | -5.12% | |
| Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference | Press release | PR Newswire | — | -3.97% | |
| Avaí Bio and Austrianova Begin Production of Master Cell Bank for Klotho Anti-Aging Therapy Under GMP Standards | Press release | PR Newswire | +1.72% | +5.83% | |
| Avant Technologies Completes Rebranding with Name Change to Avaí Bio and Launch of New Website | Press release | PR Newswire | -5.04% | +0.82% | |
| Avant Technologies Evaluating Advanced Cells for Diabetes Therapy at 15th Annual EPITA Symposium | Press release | PR Newswire | +4.35% | +2.90% | |
| Avant Technologies Highlights the Critical Role of Cell Encapsulation Technology in Revolutionizing Diabetes Treatment | Press release | PR Newswire | -0.55% | -0.69% | |
| Avant Technologies and Austrianova Advancing a-Klotho Cell Therapy as Mayo Clinic Study Links Low a-Klotho Levels to Poor Cardiovascular Survival | Press release | Business Wire | +0.00% | +4.82% | |
| Avant Technologies and Austrianova Secure Exclusive License for Klotho Producing Cell Line to Advance Anti-Aging Therapies | Press release | Business Wire | +9.45% | -2.13% | |
| Avant Technologies Signs Joint Venture to Advance Cell-Based Diabetes Treatment | Press release | Business Wire | +7.69% | +3.68% | |
| Avant Technologies and Austrianova Launch Klothonova, Begin Developing Age Related Cellular Therapies Using 'Longevity Protein' Klotho | Press release | PR Newswire | +2.54% | +15.33% | |
| Avant Technologies, Inc. Bolsters Strategic Vision with Targeted Biotech Partnerships for Innovative Cell-Based Therapies | Press release | Canada Newswire | -1.56% | +0.21% | |
| Avant Technologies, Art-Islets, and Austrianova Announce Joint Venture to Advance Diabetes Treatment | Press release | Canada Newswire | +2.10% | -0.16% | |
| Avant Technologies, Inc. Issues Retraction of September 24, 2025 Press Release | Press release | Canada Newswire | — | -1.40% | |
| Avant Technologies and Austrianova Sign Joint Venture, Licensing Agreement to Advance Klotho-Based Therapies | Press release | Canada Newswire | +2.97% | +4.17% | |
| Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial | Press release | PR Newswire | -0.54% | — | |
| Avant Technologies and Ainnova Tech Advance Clinical Trial Protocol Following FDA Feedback | Press release | Canada Newswire | +0.00% | — | |
| Avant Technologies' Joint Venture Partner Presents AI Technology at Roche Ophthalmology Conference | Press release | Canada Newswire | +7.30% | +3.04% | |
| Avant Technologies and JV Partner, Ainnova, Complete Pivotal Meeting with U.S. FDA | Press release | Canada Newswire | +4.10% | +6.22% | |
| Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America | Press release | Canada Newswire | +3.77% | +6.79% | |
| Avant Technologies and JV Partner, Ainnova, Prepare for Key FDA Milestone with Next Week's Pre-Submission Meeting | Press release | Canada Newswire | +2.82% | +7.27% | |
| Avant Technologies Creating New Company for Expansion of Diabetes Program | Press release | Canada Newswire | -1.60% | -4.87% | |
| Avant Technologies' JV Partner, Ainnova, Begins Diabetic Retinopathy Screenings with Leading Pharmacies | Press release | Canada Newswire | -5.66% | -2.92% | |
| Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development | Press release | ACCESS Newswire | +0.00% | +2.70% | |
| Avant Technologies Signs Letter of Intent for a Business Combination | Press release | Canada Newswire | +0.00% | -5.16% | |
| Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development | Press release | Canada Newswire | +0.00% | -2.97% | |
| Avant Technologies and Ainnova Explore Integrating Early Detection of Dementia into AI-Powered Preventative Screening Platform | Press release | ACCESS Newswire | +3.27% | +5.16% | |
| Avant Technologies and Ainnova Explore Integrating Early Detection of Dementia into AI-Powered Preventative Screening Platform | Press release | Canada Newswire | +3.27% | +5.16% | |
| Avant Technologies and Ainnova in Talks to Obtain Innovative Technology in Preventative Health Reporting | Press release | Canada Newswire | +0.00% | +14.93% | |
| Avant Technologies and Ainnova Tech Begin Acquisition Talks Ahead of FDA Pre-Submission Meeting | Press release | Canada Newswire | +0.00% | +1.17% | |
| Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company's Vision AI Platform Technology | Press release | Canada Newswire | +0.00% | -4.17% | |
| Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company’s Vision AI Platform Technology | Press release | ACCESS Newswire | +0.00% | -4.17% | |
| Avant Technologies and Ainnova Request Pre-Submission Meeting with US FDA for VisionAI Platform Technology | Press release | Canada Newswire | -23.28% | +3.02% | |
| Avant Technologies and JV Partner, Ainnova, Accelerate Expansion Across Latin America Following Key Role at Healthcare Innovation Summit | Press release | Canada Newswire | +0.00% | +8.11% | |
| Avant Technologies Partner, Ainnova, to Sponsor and Present at 2025 Healthcare Innovation Summit in Mexico City | Press release | Canada Newswire | +0.00% | +25.75% | |
| Avant Technologies and Ainnova Begin Designing Clinical Trial Protocol for Company's Vision AI Platform | Press release | Canada Newswire | +0.00% | +0.00% | |
| Avant Technologies and JV Partner, Ainnova, Strategically Align with Apollo Hospitals to Advance AI in Healthcare | Press release | ACCESS Newswire | +0.00% | +18.10% | |
| Avant Technologies Reaches Global Development and Licensing Deal with Partner, Ainnova Tech, Ahead of FDA Meetings | Press release | ACCESS Newswire | +0.00% | -17.81% | |
| Avant Technologies JV Partner to Speak at AI Revolution in Healthcare Summit in Dubai | Press release | ACCESS Newswire | +0.00% | +2.44% | |
| Avant Technologies and Ainnova Advance Toward FDA Clinical Trial with Selection of Top CRO | Press release | ACCESS Newswire | +0.00% | +7.46% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AVAI section they belong to.
Where else AVAI is measured.
AVAI earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is AVANT TECHNOLOGIES INC's median reaction calculated?
Every labeled AVAI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 134 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of AVAI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AVAI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.